Corticosteroids, heart failure, and hypertension: A role for immune cells?

Endocrinology

Volumn 153, Issue 12, 2012, Pages 5692-5700

  Shen, Jimmy Z ^a   Young, Morag J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; ALDOSTERONE RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 23; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR SYSTEM; CARDITIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ELECTROLYTE BALANCE; EPITHELIUM CELL; FIBROBLAST; FLUID BALANCE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TRANSGENIC MOUSE;

ADRENAL CORTEX HORMONES; ANIMALS; ELECTROLYTES; HEART FAILURE; HUMANS; HYPERTENSION; IMMUNE SYSTEM; INFLAMMATION; LIGANDS; MACROPHAGES; MODELS, BIOLOGICAL; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; SALTS; SIGNAL TRANSDUCTION; WATER;

EID: 84870182357     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1780     Document Type: Short Survey

References (105)

1. Mendis S, Puska P, Norrving B 2011 Global atlas on cardiovascular disease prevention and control, 2011 edition. Geneva, Switzerland: World Health Organization
2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ 2004 Trends in heart failure incidence and survival in a community-based population. JAMA 292:344-350
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS 2002 Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:1397-1402
4. Curtis LH, Greiner MA, Hammill BG, Kramer JM, Whellan DJ, Schulman KA, Hernandez AF 2008 Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 168:2481-2488
5. Bundkirchen A, Schwinger RH 2004 Epidemiology and economic burden of chronic heart failure. Eur Heart J Suppl 6:D57-D60
6. 2005 The shifting burden of cardiovascular disease in Australia, 2005 edition. National Heart Foundation of Australia
7. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ 2009 Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54:537-543
8. Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LM, Young MJ 2012 Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 153:3416-3425
9. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM 2010 Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350-3364
10. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM 1985 Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318:635-641
11. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
12. Wehling M 1997 Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 59:365-393
13. Cato AC, Nestl A, Mink S 2002 Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002:re9
14. Funder JW 2005 Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 10:15-22
15. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C 1988 Localisation of 11 β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989
16. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
17. Walker BR 2007 Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545-559
18. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD 2003 Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108:2400-2406
19. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M 2005 Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97:434-442
20. Jaffe IZ, Mendelsohn ME 2005 Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96:643-650
21. Mihailidou AS, Mardini M, Funder JW 2004 Rapid, nongenomic effects of aldosterone in the heart mediated by ε protein kinase C. Endocrinology 145:773-780
22. Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JM, Danser AH 2005 Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol 145:664-671
23. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC 1994 High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21:315-318
24. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F 2006 A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48:2293-2300
25. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248
26. Gomez-Sanchez EP 1986 Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 118:819-823
27. Gómez-Sánchez EP, Venkataraman MT, Thwaites D, Fort C 1990 ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 258:E649-E653
28. Skøtt O, Uhrenholt TR, Schjerning J, Hansen PB, Rasmussen LE, Jensen BL 2006 Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol Ther 111:495-507
29. McCurley A, Jaffe IZ 2012 Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 350:256-265
30. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ 2012 Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18:1429-1433
31. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL 2012 T Regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59:324-330
32. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717
34. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B 2011 Group E-HS eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21
35. Rousseau MF, Gurné O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM 2002 Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 40:1596-1601
36. Funder JW 2010 Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis 52:393-400
37. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M 2007 Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 292:R946-R954
38. Yoshida M, Ma J, Tomita T, Morikawa N, Tanaka N, Masamura K, Kawai Y, Miyamori I 2005 Mineralocorticoid receptor is over-expressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 11:12-16
39. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT 2002 Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 161:1773-1781
40. Young M, Funder JW 2004 Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/saltt-reated rats. Endocrinology 145:3153-3157
41. Brilla CG, Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893-901
42. Hou J, Kato H, Cohen RA, Chobanian AV, Brecher P 1995 Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase. J Clin Invest 96:2469-2477
43. Oestreicher EM, Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK 2003 Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 108:2517-2523
44. Cohn JN, Ferrari R, Sharpe N 2000 Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569-582
45. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, Lu L, Bhattacharya SK, Postlethwaite AE, Weber KT 2003 Aldosteronism and peripheral blood mononuclear cell activation. Circ Res 93:e124-e135
46. Young MJ, Moussa L, Dilley R, Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144:1121-1125
47. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasen-fuss G, Shah AM 2003 Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41:2164-2171
48. Li JM, Shah AM 2003 Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 278:12094-12100
49. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM 2002 Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40:477-484
50. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM 2006 Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20:1546-1548
51. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT 2010 From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res 33:1091-1101
52. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J 2011 Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction / clinical perspective. Circulation 123:400-408
53. Rickard AJ, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, Reichelt ME, Delbridge LM, Young MJ 29 October 2012 Cardiomyocyte mineralocorticoid receptors are essential for DOC/salt-mediated inflammation and cardiac fibrosis. Hypertension 10.1161/HYPERTENSIONAHA.112.203158
54. Brilla CG, Zhou G, Matsubara L, Weber KT 1994 Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26:809-820
55. Weber KT, Brilla CG 1992 Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res Cardiol 87(Suppl 1):291-301
56. Young MJ, Funder JW 1996 The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 271:E883-E888
57. Young M, Head G, Funder J 1995 Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269:E657-E662
58. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M 2006 Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47:656-664
59. Fejes-Tóth G, Náray-Fejes-Tóth A 2007 Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology 148:1502-1510
60. Latouche C, Sainte-Marie Y, Steenman M, Castro Chaves P, Naray-Fejes-Toth A, Fejes-Toth G, Farman N, Jaisser F 2010 Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology 151:4467-4476
61. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, Barreto F, Bauersachs J, Schütz G, Hein L 2011 Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57:746-754
62. Armanini D, Strasser T, Weber PC 1985 Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol 248:E388-E390
63. Herrada AA, Contreras FJ, Marini NP, Amador CA, González PA, Cortés CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF, Fardella CE, Kalergis AM 2010 Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 184:191-202
64. Bergmann A, Eulenberg C, Wellner M, Rolle S, Luft F, Kettritz R 2010 Aldosterone abrogates nuclear factor κB-mediated tumor necrosis factor α production in human neutrophils via the mineralocorticoid receptor. Hypertension 55:370-379
65. Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A 2001 11β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 167:30-35
66. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, McMahon EG, Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802-H1810
67. Chow LH, Ye Y, Linder J, McManus BM 1989 Phenotypic analysis of infiltrating cells in human myocarditis. An immunohistochemical study in paraffin-embedded tissue. Arch Pathol Lab Med 113:1357-1362
68. Vilahur G, Hernández-Vera R, Molins B, Casaní L, Duran X, Padró T, Badimon L 2009 Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells. J Thromb Haemost 7:485-493
69. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M 2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development. Circulation 109:2213-2220
70. Lawrence T, Natoli G 2011 Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11:750-761
71. Murray PJ, Wynn TA 2011 Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723-737
72. Troidl C, Möllmann H, Nef H, Masseli F, Voss S, Szardien S, Willmer M, Rolf A, Rixe J, Troidl K, Kostin S, Hamm C, Elsässer A 2009 Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 13:3485-3496
73. Biswas SK, Mantovani A 2010 Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896
74. Mosser DM, Edwards JP 2008 Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969
75. Barron L, Wynn TA 2011 Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 300:G723-G728
76. Frieler RA, Meng H, Duan SZ, Berger S, Schütz G, He Y, Xi G, Wang MM, Mortensen RM 2011 Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42:179-185
77. Chu PY, Zatta A, Kiriazis H, Chin-Dusting J, Du XJ, Marshall T, Kaye DM 2011 CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail4:651-658
78. Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T, Frantz S 2012 Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation 125:1652-1663
79. Zhu J, Yamane H, Paul WE 2010 Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28:445-489
80. Obhrai JS, Oberbarnscheidt MH, Hand TW, Diggs L, Chalasani G, Lakkis FG 2006 Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs. J Immunol 176:4051-4058
81. O'Garra A, Gabryšová L, Spits H 2011 Quantitative events determine the differentiation and function of helper T cells. Nat Immunol 12:288-294
82. Kanellakis P, Dinh TN, Agrotis A, Bobik A 2011 CD4+CD25+Foxp3+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J Hypertens 29:1820-1828
83. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I 1999 Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8:265-277
84. Brown NJ 2008 Aldosterone and vascular inflammation. Hypertension 51:161-167
85. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG 2007 Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med 204:2449-2460
86. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG 2010 Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55:500-507
87. Stowasser M 2001 New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 28:783-791
88. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME 2010 Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 120:3891-3900
89. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL 2005 Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 25:2106-2113
90. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, Münzel T 2011 Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 124:1370-1381
91. Tsai S, Hollenbeck ST, Ryer EJ, Edlin R, Yamanouchi D, Kundi R, Wang C, Liu B, Kent KC 2009 TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol 297:H540-H549
92. Suwanabol PA, Seedial SM, Zhang F, Shi X, Si Y, Liu B, Kent KC 2012 TGF-β and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 302:H2211-H2219
93. Maddur MS, Miossec P, Kaveri SV, Bayry J 2012 Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181:8-18
94. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK 2006 Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238
95. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR 2007 IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967-974
96. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R 2007 Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950-957
97. Fogg DK, Sibon C, Miled C, Jung S, Aucouturier P, Littman DR, Cumano A, Geissmann F 2006 A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311:83-87
98. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K 2010 Development of monocytes, macrophages, and dendritic cells. Science 327:656-661
99. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ 2010 Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension/clinical perspective. Circulation 122:2529-2537
100. Littman DR, Rudensky AY 2010 Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140:845-858
101. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H 2007 Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317:256-260
102. Yang J, Yang X, Zou H, Chu Y, Li M 2011 Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford) 50:1366-1372
103. Kong N, Lan Q, Chen M, Wang J, Shi W, Horwitz DA, Quesniaux V, Ryffel B, Liu Z, Brand D, Zou H, Zheng SG 2012 Antigen-specific TGF-β-induced regulatory T cells but not natural Tregs ameliorate autoimmune arthritis by shifting the balance of Th17 toward Treg cells. Arthritis Rheum 64:2548-2558
104. Lin FJ, Jiang GR, Shan JP, Zhu C, Zou J, Wu XR 2012 Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest 72:221-229
105. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL 2011 T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57:469-476